OVERWEIGHT
Clinical trials for OVERWEIGHT explained in plain language.
Never miss a new study
Get alerted when new OVERWEIGHT trials appear
Sign up with your email to follow new studies for OVERWEIGHT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a Two-Drug combo tip the scales against obesity?
Disease control Not yet recruitingThis early-stage trial is testing whether a new drug called macupatide, given alone or with another drug called eloralintide, is safe and well-tolerated in Japanese adults with obesity or overweight who do not have type 2 diabetes. Participants will receive multiple doses and sta…
Matched conditions: OVERWEIGHT
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New team approach aims to simplify care for heart and kidney health
Disease control Not yet recruitingThis study tests a 6-month program where patients work with a pharmacist and their primary care doctor to make shared decisions about medications and lifestyle. The goal is to see if this team-based approach improves heart and kidney health scores and medication adherence. The st…
Matched conditions: OVERWEIGHT
Phase: EARLY_PHASE1 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new injection help tackle obesity? a trial investigates
Disease control Not yet recruitingThis early-stage trial is testing an investigational drug called BI 3034701 in people with overweight or obesity who also have at least one weight-related health condition. The main goal is to see how safe and tolerable the drug is when given by injection, and to understand how i…
Matched conditions: OVERWEIGHT
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new injection help shed pounds? a trial investigates
Disease control Not yet recruitingThis clinical trial is testing an experimental drug called ABBV-295 to see if it can help adults with obesity or overweight lose weight. The study will compare different doses of the drug against a placebo (a dummy injection) to measure its effect on body weight over 32 weeks. Pa…
Matched conditions: OVERWEIGHT
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can dance beat pilates for lasting Weight-Loss motivation?
Disease control Not yet recruitingThis study compares how well women with overweight or obesity stick to a 10-week dance-based exercise program versus a clinical Pilates program. Participants, aged 18-60 with a BMI between 25 and 35, will be randomly assigned to one of the two supervised group programs, held twic…
Matched conditions: OVERWEIGHT
Phase: NA • Sponsor: Pamukkale University • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Talking it off: can counseling sessions tip the scale on obesity?
Disease control Not yet recruitingThis study tests whether motivational interviewing—a supportive, goal-oriented counseling style—can help overweight and obese adults improve their eating habits, health literacy, and body measurements. Participants will receive either four structured counseling sessions plus rout…
Matched conditions: OVERWEIGHT
Phase: NA • Sponsor: Sakarya University • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can four simple diet hacks boost digital weight loss? stanford launches reset trial
Disease control Not yet recruitingThe Reset trial, led by Stanford University, aims to find the best combination of four dietary strategies for weight loss in a fully digital program. 208 adults with overweight or obesity will receive a 12-week remote intervention that includes daily self-weighing, weekly lessons…
Matched conditions: OVERWEIGHT
Phase: NA • Sponsor: Stanford University • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a new injection help shed excess weight?
Disease control Not yet recruitingThis clinical trial is testing an investigational medicine called cagrilintide to see how well it helps people with overweight or obesity lose weight. Participants will receive either cagrilintide or a placebo (an inactive substance) by injection, and their weight change will be …
Matched conditions: OVERWEIGHT
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a new injection slow stomach emptying to curb obesity?
Disease control Not yet recruitingThis early-stage trial is testing whether an investigational drug called eloralintide can slow down how quickly the stomach empties, which may help people feel fuller longer and support weight management. The study involves about 56 adults who are overweight or have obesity but a…
Matched conditions: OVERWEIGHT
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
A daily pill for obesity? zenagamtide faces its biggest test yet.
Disease control Not yet recruitingThis phase 3 trial is testing whether an experimental once-daily oral drug called zenagamtide can safely help people with excess body weight lose weight. Around 950 adults aged 18 and older with overweight or obesity will be randomly assigned to receive either zenagamtide or a pl…
Matched conditions: OVERWEIGHT
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New weekly shot could help asian adults shed pounds
Disease control Not yet recruitingThis Phase 3 study tests whether a weekly injection called zenagamtide helps Asian adults with overweight or obesity lose weight safely. About 400 participants will receive either the drug or a placebo for several weeks. The main goal is to see how much body weight changes, with …
Matched conditions: OVERWEIGHT
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug shows promise for sustained weight loss in type 2 diabetes
Disease control Not yet recruitingThis study tests a drug called maridebart cafraglutide (MariTide) in people who are overweight or obese and also have type 2 diabetes. The goal is to see if the drug can help with long-term weight loss and blood sugar control, and to check its safety over time. Participants recei…
Matched conditions: OVERWEIGHT
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New obesity drug takes on semaglutide in major trial
Disease control Not yet recruitingThis Phase 3 trial will test whether a new drug called zenagamtide helps people with obesity lose more weight than the current treatment semaglutide. About 650 adults will receive weekly injections of either zenagamtide, semaglutide, or a placebo. The main goal is to see how much…
Matched conditions: OVERWEIGHT
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Could Legume-Enriched bread help tame blood sugar?
Disease control Not yet recruitingThis study investigates whether replacing some wheat flour with legume flours (chickpea, pea, or lentil) in Arabic bread can reduce blood sugar spikes after eating. Overweight or obese adults aged 18–65 will consume different breads and have their blood glucose and appetite measu…
Matched conditions: OVERWEIGHT
Phase: NA • Sponsor: University of Nottingham • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Online confidence course aims to get people moving against obesity
Disease control Not yet recruitingThis study tests a web-based program called Confident Moves designed to help adults with obesity increase their physical activity and improve overall health. About 348 adults aged 18-64 with a BMI of 25 or higher will be enrolled. Participants will use an online platform with sel…
Matched conditions: OVERWEIGHT
Phase: NA • Sponsor: Iowa State University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New obesity drug SA030 enters first human safety trial
Disease control Not yet recruitingThis early-stage study tests a single dose of SA030 injection in 40 overweight or obese adults aged 18–55. The main goal is to check safety and how the body handles the drug. It is the first time SA030 is given to humans, so results will guide future research.
Matched conditions: OVERWEIGHT
Phase: PHASE1 • Sponsor: Suzhou Siran Biotechnology Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New weekly shot aims to beat semaglutide for weight loss and diabetes
Disease control Not yet recruitingThis Phase 3 trial tests a new once-weekly injection, NNC0487-0111, against the approved drug semaglutide in 1000 adults with overweight or obesity and type 2 diabetes. Participants receive two weekly shots (active drug plus placebo) to see if the new drug is safe and leads to gr…
Matched conditions: OVERWEIGHT
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Hydrogen water tested as a Weight-Loss aid
Disease control Not yet recruitingThis study tests whether drinking hydrogen-rich water every day can help adults who are overweight improve their body composition and metabolism. Researchers will compare hydrogen water to plain water in 120 participants over a period of time. The goal is to see if this simple dr…
Matched conditions: OVERWEIGHT
Phase: NA • Sponsor: Center for Health Sciences, Serbia • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
A Blue-Green algae could ease menopause symptoms — a trial puts it to the test
Symptom relief Not yet recruitingThis trial tests whether taking 2 grams of spirulina daily for 8 weeks can improve metabolic health, body composition, sleep quality, and mood in mildly overweight postmenopausal women. Researchers will measure changes in blood sugar, cholesterol, weight, waist size, depression s…
Matched conditions: OVERWEIGHT
Phase: NA • Sponsor: Halic University • Aim: Symptom relief
Last updated Jul 24, 2026 00:00 UTC
-
Easier diet tracking may help people lose weight without counting every calorie
Symptom relief Not yet recruitingThis study tests whether tracking only high-calorie, low-nutrition foods (Red Zone Foods) works as well as tracking all foods and calories for weight loss. About 328 adults with overweight or obesity will use a digital program for 12 months. The goal is to see if a simpler approa…
Matched conditions: OVERWEIGHT
Phase: NA • Sponsor: Stanford University • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
Stair snacks: tiny workouts, big heart gains?
Symptom relief Not yet recruitingThis study looks at whether brief, intense stair-climbing sessions (called 'exercise snacks') can improve blood vessel function and body composition in overweight adults aged 18-35. Sixty participants will be split into four groups, including a no-exercise control group, for 6-8 …
Matched conditions: OVERWEIGHT
Phase: NA • Sponsor: Weifang Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 12:27 UTC
-
New study: therapy and app may curb emotional eating in overweight adults
Symptom relief Not yet recruitingThis study looks at whether a type of talk therapy called Acceptance and Commitment Therapy (ACT), combined with a mobile app, can help overweight people who eat in response to emotions like stress or sadness. About 78 adults will be split into groups: some get group therapy, som…
Matched conditions: OVERWEIGHT
Phase: NA • Sponsor: Saglik Bilimleri Universitesi • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
Does injection location matter for a new Weight-Loss drug? a trial investigates
Knowledge-focused Not yet recruitingThis early-stage trial is testing how an experimental drug called PF-08653945 enters the bloodstream when injected into different areas of the body. Researchers will give a single dose to adults who are overweight or obese and measure drug levels in the blood over time. The goal …
Matched conditions: OVERWEIGHT
Phase: PHASE1 • Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Obesity drug UBT251 put to the test: will it clash with common meds?
Knowledge-focused Not yet recruitingThis study investigates whether UBT251, an experimental drug for overweight or obesity, changes how the body processes other medications like warfarin, caffeine, and midazolam. Researchers will give UBT251 to 44 adults with a BMI between 27 and 39.9, then measure levels of these …
Matched conditions: OVERWEIGHT
Phase: PHASE1 • Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
New drug interaction study could shape future obesity treatments
Knowledge-focused Not yet recruitingThis study investigates whether an experimental drug called UBT251 changes how the body processes oral contraceptives and how quickly the stomach empties. It involves women who cannot become pregnant and have overweight or obesity. The goal is to understand if UBT251 can be safel…
Matched conditions: OVERWEIGHT
Phase: PHASE1 • Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Could shedding pounds boost your job performance? study investigates weight, lifestyle, and work
Knowledge-focused Not yet recruitingThis observational study looks at how being overweight or obese, and changes in lifestyle, impact work performance, quality of life, and well-being in medical residents. Researchers will track 600 participants for 12 months, measuring body weight, lifestyle habits, and using ques…
Matched conditions: OVERWEIGHT
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New obesity drug tested in people with liver problems
Knowledge-focused Not yet recruitingThis early-stage study is testing a new medicine for overweight and obesity. The main goal is to see how the drug behaves in people with different levels of liver function, from normal to severely reduced. About 35 adults aged 18-80 will take a single dose, and researchers will m…
Matched conditions: OVERWEIGHT
Phase: PHASE1 • Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New Weight-Loss drug tested in kidney patients
Knowledge-focused Not yet recruitingThis early study will test a single dose of the experimental drug HDM1005 in 30 overweight or obese adults, some with moderate or severe kidney disease and some with healthy kidneys. The goal is to see how kidney function affects the drug's levels in the body and to check for saf…
Matched conditions: OVERWEIGHT
Phase: PHASE1 • Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Study reveals how extra weight changes anesthesia effects
Knowledge-focused Not yet recruitingThis study watches how body fat and muscle affect the way anesthetic drugs work in overweight and obese patients. Researchers will measure body composition and drug levels in 2,100 adults during surgery. The goal is to understand why heavier patients may have more complications, …
Matched conditions: OVERWEIGHT
Sponsor: Second Affiliated Hospital of Wenzhou Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
New obesity drug HDM1005 put to the test: will it play nice with other meds?
Knowledge-focused Not yet recruitingThis early-stage study will test an experimental drug called HDM1005 in 42 overweight or obese adults. Researchers want to see how HDM1005 affects stomach emptying and whether it changes how the body processes common medications like metformin, atorvastatin, warfarin, and digoxin…
Matched conditions: OVERWEIGHT
Phase: PHASE1 • Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
New VA study aims to boost health programs for midlife women veterans
Knowledge-focused Not yet recruitingThis study looks at ways to help VA medical centers put proven health programs into practice for women Veterans in midlife. The programs focus on heart health, weight management, diabetes, mental health, and menopause care. Researchers will test two support strategies at 18 VA si…
Matched conditions: OVERWEIGHT
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC